CMC Biologics: Purpose-built contract services from DNA to commercial supply
CMC Biologics' CEO Mads Laustsen
It’s all in the name; three letters that spell out the reasons why CMC Biologics continues to grow its reputation as a one-stop-shop for both cell culture and microbial-based manufacturing services.
By focusing on the fundamentals of Chemistry, Manufacturing and Control requirements, CMC Biologics is arriving within sight of its vision to be a market leader in biopharmaceutical contract services. After just eight years in operation, the company is poised to challenge long established tier one competitors.
Founded in 2001, CMC Biologics was purpose-built as a contract manufacturing organization (CMO) focused on open and collaborative working relationships with customers.
“We are a truly independent solution provider,” CEO Mads Laustsen told partneringNEWS™. “We do not develop and manufacture our own biologics, nor have we entered into risk-sharing ventures. This way we can commit our full attention to our customers and take on their challenges with a high level of science, dedication and expertise to deliver a carefully customized solution.”
CMC Biologics
In 2007, CMC Biologics expanded its footprint by acquiring a facility in Seattle from Eli Lilly and successfully retaining a highly experienced biomanufacturing team, rapidly giving the company a greater international focus and capabilities to service a global client base.
Today, the combination of CMC Biologics in Copenhagen and CMC ICOS Biologics in Seattle is approaching 400 employees with about 60 percent of the staff at its Danish site and 40 percent in the United States. The customer base ranges from small-scale biotechnology start ups to large-scale pharmaceuticals spanning the globe, reaching beyond Europe and North America to include clients in Japan and Australia.
“CMC Biologics has a growing and more mature client base, and a track record to deliver on commitments that ensures repeat business, which is critical in such turbulent times,” Laustsen recently explained in a publication of International Pharmaceutical Industry.
“With the current global economic climate and industry consolidation, outsourcing of biologicals manufacture has become a more favorable option,” he explained. “Yet the commitment to outsource to contract suppliers is also more protracted. The dilemma for drug developers is that some biological CMOs have recently exited.”
“CMC has risen above this declining pool of contractors, with a strong reputation for quality of service and technical prowess,” he said. “Over the coming years, we will probably see more CMOs exiting, and only a few will continue gaining ground on the biggest suppliers.”
CBO, Bernard Chan, said CMC offers compelling reasons for choosing an outsourcing model.
CMC Biologics' CBO Bernard Chan
“We get things right the first time, and are highly successful trouble-shooting if technical issues arise,” he said. The repertoire of protein-based drugs that CMC Biologics has been exposed to over the years provides a greater depth of bioprocessing and biomanufacturing know-how, which many companies lack.
Chan explained, “As a customer’s product progresses towards commercial approval, CMC Biologics offers a variety of scales of operation to design a strategy ensuring an appropriate route for scale-up, with expansion potential at sites in both Seattle and Copenhagen.”
Finally, Lausten added that “CMC Biologics offers a number of options for leveraging on strategic alliances. For example, customers can implement a biomanufacturing strategy that ensures reserved capacity over a longer period of time at a reduced financial risk, while the progress of any particular drug candidate remains uncertain. Alternatively, customers may be looking for future scale-up expansion on a joint risk-sharing basis with a contractor such as CMC Biologics, which remains in a position to place such a customer at the highest of priorities.”
Related Posts
No related posts.